Series C round brings $30mm to Pathwork Diagnostics
New buyer Alta Partners led a $30mm Series C round for Pathwork Diagnostics Inc. (molecular tests for cancer), and takes a seat on the company's board. Existing investors Abingworth, Advent Venture Partners, Novus Ventures, Prospect Venture Partners, and Venrock also participated. Pathwork will use the proceeds to launch its Pathwork tissue-of-origin diagnostic, the first of its kind to gain FDA approval.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com